Cellares Corporation, a life sciences technology company that automates cell therapy manufacturing, has secured $82 million in a Series B round, bringing total funding to date to $100 million. The round was led by new investor Decheng Capital and co-led by existing investor Eclipse Ventures. Skyviews Life Science joined as a new investor, with previous investor 8VC also participating.   This latest funding will accelerate development of the Cell Shuttle, Cellares’ scalable factory-in-a-box...